Retatrutide + Cagrilintide calculator
An investigational pairing of the triple agonist retatrutide with the amylin analog cagrilintide. No combined product is approved.
Also known as: Triple agonist + amylin combination
FDA status — not an approved drug Not FDA-approved. Neither retatrutide nor cagrilintide is approved, and no combined product exists as an approved drug.
Schedule Retatrutide + Cagrilintide → Set your dosing schedule and get a phone notification when each dose is due. Free.
What Retatrutide + Cagrilintide is
Retatrutide with cagrilintide is an investigational concept pairing a triple GIP/GLP-1/glucagon agonist with an amylin analog. Neither component is approved, and no clinical trial has evaluated the two together. Combinations sold by research suppliers are unregulated and not standardized.
Research depth: 1/5 No trials of this combination; evidence is limited to the individual components. Human trials: None for the combination. This measures how much has been studied — counting animal and laboratory work — not whether it works for you.
How Retatrutide + Cagrilintide works
Each engages a separate set of appetite-regulating receptors: retatrutide activates GIP, GLP-1, and glucagon receptors, while cagrilintide activates amylin receptors. The theoretical appeal is additive appetite suppression and energy expenditure, but the combined safety and efficacy are untested.
Retatrutide + Cagrilintide side effects
Commonly reported
- No data on the combination specifically
- Gastrointestinal effects expected from both components
- Increased heart rate from the glucagon activity
Serious — seek medical care
- Unstudied combination — safety and interactions unknown
- Quality and dosing variability in unregulated blended products
- Pancreatitis, gallbladder, and cardiovascular risks under study for the individual agents
This list is not exhaustive. Report anything unexpected to the clinician who prescribed it. If you have severe abdominal pain, trouble breathing, or signs of an allergic reaction, seek care the same day. See also our guide to peptide side effects by class.
A worked example
A 10 mg vial reconstituted with 2 mL of bacteriostatic water gives 5 mg/mL. A 2400 mcg dose is then 0.48 mL — about 48 units on a 100-unit insulin syringe, giving roughly 4 doses per vial before accounting for residual volume left in the vial and syringe.
Prefer paper? Download the printable Retatrutide + Cagrilintide dosing chart (PDF) — every vial size and water volume in syringe units, with the same review byline as this page. All charts →
Commonly cited dose range
Figures circulating for Retatrutide + Cagrilintide run from 2400 mcg to 2400 mcg. No established dosing exists for this combination — it is an investigational concept, not an approved or standardized product. Figures shown reflect the cagrilintide component's published dosing. Any actual product is compounded and unstandardized.
Read this as reference information, not instruction. These numbers describe what is commonly discussed, not what is right for any individual. Dose, frequency, and whether to use Retatrutide + Cagrilintide at all are decisions for a licensed clinician who knows your history.
Common questions
Is retatrutide with cagrilintide a real drug?
Not an approved one. Both components are investigational, and there is no standardized or approved combination product. Blends sold by suppliers are unregulated and vary in composition.
Why combine them?
They act on different receptors — retatrutide on GIP/GLP-1/glucagon, cagrilintide on amylin. The rationale is additive weight loss, but no controlled trial has tested this specific pairing.